Disclosures for "Effects of Comorbid Insulin-Dependent Diabetes Mellitus (IDDM) in Symptom Severity, Disease Progression, and Treatment Response of Patients with Stiff Person Syndrome (SPS) "
-
Dr. Porreca has nothing to disclose.
-
Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx,. Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.